0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

º¹ÇÕÈ­Çпä¹ýÀ» ¹ÞÀº ¹Ì¸¸¼º °Å´ë B¼¼Æ÷ ¸²ÇÁÁ¾ ȯÀÚÀÇ È£Áß±¸°¨¼ÒÁõ ¹ß»ý¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎ: ȯÀÚ-´ëÁ¶±º ¿¬±¸

Factors Associated with Chemotherapy-induced Neutropenia in Diffuse Large B-cell Lymphoma Patients Undergoing Combination Chemotherapy: A Case-Control Study

Á¾¾ç°£È£¿¬±¸ 2022³â 22±Ç 3È£ p.153 ~ 162
KMID : 1035120220220030153
ÀÓ¼ö¿¬ ( Lim Su-Yeon ) - Chonnam National University Hwasun Hospital Department of Nursing

ÃÖÀÚÀ± ( Choi Ja-Yun ) - Chonnam National University College of Nursing

Abstract

Purpose: This study aimed to identify the factors associated with chemotherapy-induced neutropenia (CIN) in diffuse large B-cell lymphoma (DLBCL) patients undergoing combination chemotherapy.

Methods: A total of 111 patients with DLBCL participated in this study at C University Hospital. The CIN group consisted of patients with an absolute neutrophil count (ANC) lower than 1,000 cells/¥ìL. Clinical factors, the level of depression, and the level of healthy lifestyle were measured on the chemotherapy administration day, and the ANC was measured on the next follow-up day.

Results: Binary logistic regression analysis showed that the factors associated with CIN in DLBCL were the presence of B symptoms at diagnosis (¥â=4.69) and low-risk CIN regimen (¥â=0.10) among clinical factors, and the level of healthy lifestyle (¥â=0.17).

Conclusion: Oncology nurses have to focus on the patients vulnerable to CIN having B symptoms at diagnosis, receiving a low-risk CIN regimen, and showing non-adherence to healthy lifestyle practice. Administration of granulocyte colony-stimulating factor can be considered for the patients receiving low-risk CIN regimen to reduce CIN. Education programs including healthy lifestyle practice to improve the immune system should be applied to the DLBCL patients.
KeyWords
¹Ì¸¸¼º °Å´ë B ¼¼Æ÷ ¸²ÇÁÁ¾, Ç×¾ÏÈ­Çпä¹ý À¯¹ß È£Áß±¸°¨¼ÒÁõ, ¿µÇâ¿äÀÎ
Diffuse large B-cell lymphoma, Chemotherapy-induced febrile neutropenia, Precipitating factors
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed